ReviewCNS drugs2018
Role of Exogenous Progesterone in the Treatment of Men and Women with Substance Use Disorders: A Narrative Review.
Review in CNS drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 38 citations in OpenAlex.
- Attentional bias to alcohol-related cues: effects of menstrual cycle phase and sex differences.Psychopharmacology · 2025Trial
- Exogenous progesterone for smoking cessation in men and women: a pilot double-blind, placebo-controlled randomized clinical trial.Addiction (Abingdon, England) · 2019Trial
- Progesterone Attenuates the Stress Response in Individuals with Alcohol Dependence and Post-Traumatic Stress Disorder - A Pilot Study.Journal of dual diagnosisTrial
- Menstrual Cycle and Progesterone-to-Estradiol Ratio Associated With Loss of Control and Craving in Alcohol Use Disorder: A Sex-Segregating Longitudinal Study.Addiction biology · 2026Observational
- Exploring hormonal influences on nicotine craving and use across the perinatal period: A prospective longitudinal study.Drug and alcohol dependence reports · 2026Article
- Ovarian hormones, hormonal contraceptives and reward processing.BJPsych advances · 2026Article
- The role of neuroactive steroids in psychiatric and neurological disorders: Neurobiology and therapeutic perspectives.Neuroscience and biobehavioral reviews · 2025Review
- Estradiol protects against pain-facilitated fentanyl use via suppression of opioid-evoked dopamine activity in males.Neuron · 2025Article
- Nicotine is an Immunosuppressant: Implications for Women's Health and Disease.Journal of neuroimmunology · 2024Review
- The Potential Health Risks and Benefits of Progesterone in the Transgender Woman Population-A Narrative Review.Journal of clinical medicine · 2024Review
- Prevention of postpartum methamphetamine use with micronized progesterone trial (PROMPT): A pilot randomized controlled trial protocol.Contemporary clinical trials communications · 2024Article
- The role of neurosteroids in posttraumatic stress disorder and alcohol use disorder: A review of 10 years of clinical literature and treatment implications.Frontiers in neuroendocrinology · 2024Review
- Mifepristone decreases nicotine intake in dependent and non-dependent adult rats.Journal of psychopharmacology (Oxford, England) · 2024Article
- The role of sex hormones in targeting stress-induced tobacco craving, stress-reactivity, and smoking with guanfacine among women who smoke.Addiction neuroscience · 2023Article
- Sex/Gender Differences in the Time-Course for the Development of Substance Use Disorder: A Focus on the Telescoping Effect.Pharmacological reviews · 2023Review
- Estradiol-dependent hypocretinergic/orexinergic behaviors throughout the estrous cycle.Psychopharmacology · 2023Review
- Estrous cycle and hormone regulation of stress-induced reinstatement of reward seeking in female mice.Addiction neuroscience · 2022Article
- Within-person decline in pregnancy smoking is observable prior to pregnancy awareness: Evidence across two independent observational cohorts.Addiction biology · 2022Observational
- Barriers to Accessing Addiction Treatment for Women at Risk of Homelessness.Frontiers in global women's health · 2022Article
- Pilot examination of stress, heart rate variability, and alcohol craving and use among female veterans.Frontiers in psychiatry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Substance use disorders (SUDs) remain problematic as many individuals are untreated or do not benefit from the currently available interventions. Thus, there is an urgent need to develop novel pharmacological interventions to treat SUDs. Evidence suggests that the female sex hormone, progesterone, attenuates the craving for and the euphoric effects of drugs of abuse. Research to date has demonstrated that progesterone may modulate responses to drugs of abuse and may have utility as a novel treatment for SUDs. A literature search was conducted to identify and examine studies that administered exogenous progesterone. Sixteen publications were identified, exploring the utility of exogenous progesterone or its metabolite, allopregnanolone, among a range of substances, including amphetamines (one study), benzodiazepines (one study), cocaine (nine studies), and tobacco/nicotine (five studies). Results indicated that exogenous progesterone and, its metabolite allopregnanolone, demonstrated preliminary efficacy as a treatment for substance use in both men and women. Notably, progesterone appears to target negative affect and augment cognitive functioning, especially among female substance users. Additional research is needed to explore the potential use of exogenous progesterone and allopregnanolone in the treatment of SUDs, including that associated with alcohol and opioids, but considering the current promising findings, exogenous progesterone and allopregnanolone may have utility as novel pharmacological treatments for SUDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.